A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Colorectal Cancer|Non-small-cell Lung Carcinoma
Interventions: DRUG: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|DRUG: Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles
Sponsor: Merck Sharp & Dohme LLC